P/E ratio for BELLUS Health (BLU)
P/E ratio as of April 2024 (TTM): -20.8
According to BELLUS Health's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -20.7606. At the end of 2022 the company had a P/E ratio of -12.5.
P/E ratio history for BELLUS Health from 2021 to 2019
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -12.5 | 38.55% |
| 2021 | -8.99 | 63.43% |
| 2020 | -5.50 | -59.67% |
| 2019 | -13.6 | -30.42% |
| 2018 | -19.6 | 23.53% |
| 2017 | -15.9 | 66.89% |
| 2016 | -9.51 | -103% |
| 2015 | 317 | -938.77% |
| 2014 | -37.8 | 70.66% |
| 2013 | -22.2 | 2248.8% |
| 2012 | -0.9436 | -129.34% |
| 2011 | 3.22 | -340.6% |
| 2010 | -1.34 | -57.3% |
| 2009 | -3.13 | 611.52% |
| 2008 | -0.4400 | -67.1% |
| 2007 | -1.34 | -107.67% |
| 2006 | 17.4 | 59.37% |
| 2005 | 10.9 | -39.97% |
| 2004 | 18.2 | -128.74% |
| 2003 | -63.4 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 ORIC Pharmaceuticals
ORIC | -4.36 | -78.99% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.